California Public Employees Retirement System Has $35.23 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

California Public Employees Retirement System decreased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 333,503 shares of the medical equipment provider’s stock after selling 31,358 shares during the period. California Public Employees Retirement System’s holdings in Zimmer Biomet were worth $35,228,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Dunhill Financial LLC raised its position in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares in the last quarter. Stonebridge Financial Group LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $25,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth $39,000. OFI Invest Asset Management bought a new position in shares of Zimmer Biomet in the fourth quarter worth $40,000. Finally, SRS Capital Advisors Inc. raised its stake in Zimmer Biomet by 146.9% in the fourth quarter. SRS Capital Advisors Inc. now owns 479 shares of the medical equipment provider’s stock valued at $51,000 after purchasing an additional 285 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ZBH. Raymond James decreased their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their target price for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. JMP Securities reiterated a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Stifel Nicolaus upped their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $112.54 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $130.89. The business’s 50 day simple moving average is $107.35 and its 200 day simple moving average is $107.18. The stock has a market capitalization of $22.40 billion, a PE ratio of 25.29, a PEG ratio of 1.95 and a beta of 1.04.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the firm earned $2.20 earnings per share. As a group, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is 21.57%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.70% of the stock is currently owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.